《综述参考文献》由会员分享，可在线阅读，更多相关《综述参考文献（4页珍藏版）》请在金锄头文库上搜索。
1、综述参考文献1 Jeurnink SM, Siersema PD, Steyerberg EW, et al. Predictors of complications after endoscopic retrograde cholangiopancreatography: a prognostic model for early discharge J. Surg Endosc, 2011, 25(9): 2892 一 900.2 Fazel A. Quadri A, Catalano MF, et al. Does a pancreatic duct stent prevent post-
2、ERCP pancreatitis? A prospective randomized studyJ. Gastrointest Endosc, 2003, 57(3): 291-294.3 Cotton PB, Lehman G, Vennes J, et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus J. Gastrointest Endosc, 1991, 37(3): 383-393.4 Williams EJ, Taylor S, Fairclough
3、 P, et al. Risk factors for complication following ERCP; results of a large-scale, prospective multicenter study J. Endoscopy, 2007, 39(9): 793-801.5 Hookey LC, RioTinto R, Delhaye M, et al. Risk factors for pancreatitis after pancreatic sphincterotomy: a review of 572 cases J. Endoscopy 2006, 38(7)
4、: 670-676.6 eLoughlin MT, Mitchell FMS. Sphincter of Oddi dysfunction and pancreatitis J. World J Gastroenterol, 2007, 13(47): 6333-6343.7 Deenadayalu VP, Blaut U, Watkins JL, et al. Does obesity confer an increased risk and/or more severe courses of post-ERCP pancreatitis? J. J Clin Gastroenterol,
5、2008, 42(10): 1103-1109.8 黎介寿, 李维勤. 重症急性胰腺炎手术指征和时机的再认识 J. 中国实用外 科杂志, 2003, 23(9): 513-514.9 Cheng CL, Sherman S, Watkins JL, et al. Risk factors for post-ERCP pancreatitis: A prospective Multicenter Study J. Am J Gastroenterol, 2006, 101(1): 139-147.10 Kostrzewska M, Baniukiewicz A, Wroblewski E, et
6、 al. Complications of endoscopic retrograde cholangiopancreatography (ERCP) and their risk factors J. Adv Med Sci，2011，56(1): 6-12.11 Freeman ML, Disario JA, Nelson DB, et al. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc, 2001,54: 425-34.12 Manes G,
7、Di Giorgio P, Repici A, et al. An Analysis of the Factors Associated With the Development of Complications in Patients Undergoing Precut Sphincterotomy: A Prostective, Controlled, Randomized, Multicenter Study J. Am J Gastroenterol, 2009, 104(10): 2412-2417.13 Zhang WJ，Tao YJ，Qua, ZW. Prevention of
8、post-ERCP pancreatitis J. Chinese Journal of Digestive Endoscopy, 2010, 27(12): 671-672.14 Keynes WM. A nonpancreatic source of the proteolytic-enzyme amidase and bacteriology in experimental acute pancreatitis. Ann Surg, 1980, 191: 187-99.15 Messmann H, Vogt W, Holstege A, et al. Post-ERCP pancreat
9、itis as a model for cytokine induced acute phase response in acute pancreatitis. Gut, 1997, 40: 80-5.16 Kaw M, Singh S. Serum lipase, C-reactive protein and interleukin-6 levels in ERCP-induced pancreatitis. Gastrointest Endosc, 2001, 54: 435-40.17 Tulassay Z. Somatostatin and the gastrointestinal t
10、ract. Scand J Gastroenterol,1998; Suppl 228:115-21.18 Andriulli A，Leandro G，Niro G, et a1. Phamacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis J. Gastrointest Endosc, 2000, 51(1): 1-7.19 Binmoeller KF, Dumas R, Harris AG, et al. Effect of somatostatin analog octreotide o
11、n human sphincter of Oddi. Dig Dis Sci, 1992, 37: 773-777.20 Lee KT, Lee DH, Yoo BM. The prophylactic effect of somatostatin on post-therapeutic endoscopic retrograde cholangiopancreatography pancreatitis; a randomized, multicenter controlled trial J. Pancreas, 2008, 37(4): 445-448.21 Bordas JM, Tol
12、edo V, Llach J, et al. Effects of bolus somatostatin in preventing pancreatitis after endoscopic pancreatography: results of a randomized study. Gastrointest Endosc, 1998, 47: 230-4.22 Rudin D, Kiss A, Wetz RV. Somatostatin and gabexate for post-endoscopic retrograde cholangiopancreatography pancrea
13、titis prevention: meta-analysis of randomized placebo-controlled trials J. J Gastroenterol Hepatol, 2007, 22(7): 997-983.23 Chan HH, Lai KH, Lin CK, et al. Effect of somatostatin in the prevention of pancreatic complications after endoscopic retrograde cholangiopanceatography J. J Chin Med Assoc, 20
14、08, 71(12): 605-609.24 Andriulli A, Clemente R,Solmi L, et al. Gabexate or somatostatin adminitration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial. Gastrointest Endosc, 2002; 56: 488-95.25 Francesco VD, Mariani A, Angel
15、ini G, et al. Effects of gabexate mesilate, a protease inhibitor, on human sphincter of Oddi motility. Dig Dis Sci, 2002, 47: 741-5.26 Cavallini G, Frulloni L. Antiproteasic agent in the prevention of post-ERCP pancreatitis: rational for use and clinical results. JOP, 2003, 4: 75-82.27 Zhang ZF, Yan
16、g N, Zhao G , et al. Preventive effect of ulinastatin and gabexate mesylate on post-endoscopic retrograde cholangiopancreatography pancreatitis J. Chin Med J(Engl), 2010, 123(18): 2600-2606.28 Yoo YW, Cha SW, Kim A, et al. The use of gabexate mesylate and ulinastatin for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatit
